The Food and Drug Administration is investigating whether convalescent plasma from recovered COVID-19 patients contains viable antibodies to treat SARS-CoV-2 in the sickest patients. While FDA trials continue, providers may request the plasma for investigational use in patients with the most serious and life-threatening COVID-19 infections. For more information, visit FDA.gov.

Related News Articles

Headline
The AHA’s American Society for Health Care Engineering has named Deanna Martin as its new executive director. A certified association executive, Martin has…
Headline
Hospital emergency departments treated 4.3% more nonfatal overdoses in 2017 than in 2016, with the visit rate increasing for all drugs except benzodiazepines,…
Headline
President Trump today directed the Health and Human Services Secretary, in consultation with the Secretary of Homeland Security, to use Defense…
Headline
The Departments of Justice and Health and Human Services today announced they will distribute personal protective equipment seized from hoarders to those on…
Headline
In an effort to encourage more blood donations, the Food and Drug Administration today said it is revisiting and updating several existing policies to help…
Headline
To support federal public health authorities and agencies in need of COVID-19-related data, the Health and Human Services Office for Civil Rights will not…